Form 4: Verve Therapeutics Director's Options Converted to Cash and CVRs Following Eli Lilly Merger

A Verve Therapeutics director's stock options were cancelled and converted to cash and contingent value rights following the company's merger agreement with Eli Lilly and Company.

Summary

• Reporting person Ourania Tatsis, a director of Verve Therapeutics, Inc., reported changes in beneficial ownership of derivative securities.
• The changes are a direct result of an Agreement and Plan of Merger dated June 16, 2025, involving Verve Therapeutics, Eli Lilly and Company, and Eli Lilly's indirect wholly owned subsidiary, Ridgeway Acquisition Corporation.
• At the effective time of the merger, all outstanding stock options with an exercise price less than $10.50 per share (the "Cash Consideration") were automatically cancelled.
• Holders of these "Cash-Out Stock Options" received a cash payment equal to the product of (a) the excess of the $10.50 Cash Consideration over the option's applicable exercise price, multiplied by (b) the total number of shares subject to the option.
• Additionally, holders received one non-tradeable contingent value right (CVR) for each share subject to the cancelled option.
• Specifically, 267,541 stock options with an exercise price of $5.02 and 42,200 stock options with an exercise price of $5.73 were cancelled.
• Following these transactions, the reporting person beneficially owns 0 derivative securities.

Sentiment

Score: 7

Explanation: The filing reflects the expected execution of a merger agreement, converting in-the-money options into cash and CVRs. This provides liquidity for the reporting person and aligns future incentives through CVRs, which is generally a positive outcome for option holders in an acquisition, though the non-tradeable nature of CVRs introduces some limitation.

Positives

• Reporting person received cash for in-the-money stock options, providing immediate liquidity.
• Receipt of non-tradeable contingent value rights (CVRs) offers potential future value based on specific milestones, aligning interests with the merger's success.

Negatives

• Stock options were cancelled, meaning the reporting person no longer holds direct equity upside beyond the CVRs.
• Contingent Value Rights are non-tradeable, limiting liquidity and immediate valuation.

Future Outlook

The filing indicates the completion of a merger, with future value for option holders tied to non-tradeable contingent value rights, which depend on future milestones.

Industry Context

This filing reflects a common outcome for employee and director equity awards during a corporate acquisition, where options are typically cashed out or converted into acquirer's equity or CVRs. The merger of Verve Therapeutics with Eli Lilly signifies consolidation in the biotechnology/pharmaceutical sector, particularly in gene editing or cardiovascular disease areas, given Verve's focus.

Comparison to Industry Standards

• The cancellation of in-the-money stock options for cash and CVRs is a standard practice in M&A transactions, particularly when the target company is acquired by a larger entity like Eli Lilly.
• The use of CVRs is common in biotech acquisitions to bridge valuation gaps and incentivize post-merger performance tied to specific clinical or regulatory milestones, similar to deals involving companies like Acceleron Pharma (acquired by Merck) or MyoKardia (acquired by Bristol Myers Squibb), where CVRs were also part of the consideration.
• The specific cash consideration of $10.50 per share for options with lower exercise prices indicates a premium over the exercise price, which is typical for in-the-money options in an acquisition scenario.

Stakeholder Impact

• Shareholders: The merger terms, including the $10.50 cash consideration, would have been disclosed to shareholders. This filing specifically details the impact on option holders.
• Employees/Option Holders: Employees and directors holding similar in-the-money options would experience a similar conversion to cash and CVRs, providing liquidity and potential future upside.

Next Steps

• Realization of value from contingent value rights based on future milestones.

Key Dates

Recommendation

This Form 4 details the mechanics of a director's equity conversion as part of a pre-announced merger. The primary price-sensitive event was the merger announcement itself. For investors, the stock's future performance is now largely tied to the success of the merger and the acquiring company (Eli Lilly), or the specific terms of the CVRs if they are publicly traded or have clear milestones. Since the transaction is a consequence of a merger, the immediate action for existing shareholders would have been determined by the merger terms (e.g., tendering shares). For new investors, the opportunity to invest in Verve Therapeutics as an independent entity is gone. The "hold" recommendation reflects that the stock's independent trading dynamics are now superseded by the merger process, and any investment decision would depend on the terms of the acquisition and the CVRs, if applicable, rather than the operational performance of Verve Therapeutics as a standalone entity.

Keywords

Verve Therapeutics, Eli Lilly, Merger, SEC Form 4, Stock Options, Contingent Value Rights, Corporate Governance, Director Compensation, VERV, Acquisition